Search results

Articles (6)

Journals (0)

1-6 of 6 results for datopotamab

Sort by:

Relevance

Select all

Sort by:

Relevance

Retricted access

Review article

First published 2025

Targeting TROP2 Across Solid Tumors: The Clinical Profile and Role of Datopotamab Deruxtecan

Rachel Lucky, Lauren Thornburg, Zachery Halford

Annals of Pharmacotherapy

Open access

Research article

First published 2025

TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer

Heather L. McArthur, Sara M. Tolaney, Rebecca Dent [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2025

TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR -mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib

Daniel Shao-Weng Tan, Ernest Nadal, Parneet Cheema [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2024

TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

Aditya Bardia, Lajos Pusztai, Kathy Albain [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2025

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer

Peter Schmid, Mafalda Oliveira, Joyce O’Shaughnessy [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2025

Antibody-drug conjugates outperform chemotherapy in EGFR-TKI-resistant NSCLC: a Bayesian network meta-analysis

Yueying Chen, Yanjun Du, Juan Ni [...]

Therapeutic Advances in Medical Oncology